The dramatic drop in the cost of genome sequencing, combined with rapidly evolving artificial intelligence, is moving precision medicine into mainstream healthcare. Sanjay Chikarmane, senior vice president at Illumina, told an briefing at HIMSS17 in Orlando on Monday that the US$100 genome is now in sight. Illumina is an US company focused on genetics sequencing and analysing big data for biological insights. The company is also the major partner for the UK Government's 100k Genome project, providing most of the infrastructure through a £78 million partnership with the Genomics England. During the briefing, Illumina announced a new partnership with Philips.